Disease
HR+/HER2- Breast Cancer
Hormone-receptor-positive, HER2-negative breast cancer — the largest breast cancer subtype (70.1% of US cases), defined by endocrine sensitivity and treated with endocrine therapy plus CDK4/6 inhibitors.
Total attributable cost
$22.7B
$214,664/patient
Drug spend
$2.4B
$22,727/patient
11% of total cost is drugs
Metastatic (stage IV), de novo and recurrent · US